BioMedTracker is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Informa

Legal Disclosure

COPYRIGHT AND LIMITATION OF USE

BioMedTracker ("BMT") is a financial information, news, and software service focusing on event driven biotechnology and pharmaceutical research. The Service is provided by Sagient Research Systems ("SRS").  As a condition of your use of the Service we require you to expressly be aware that our database and software were compiled, prepared, revised, selected and arranged by SRS and/or its third-party suppliers through the application of methods and standards of judgment developed and applied through the expenditure of substantial time, effort and money. Our database and software constitute valuable intellectual property and contain trade secrets of SRS and/or its third-party suppliers.

Information received through BMT may be displayed, reformatted and printed for your personal, non-commercial use or for purposes of research and related work in the ordinary course of your business. You agree not to reproduce, retransmit, distribute, disseminate, sell, publish, broadcast or circulate or commercially exploit the information received through BMT to anyone in any manner without the express written consent of SRS.

BMT displays facts, analysis and opinions relating to companies' drug pipelines deemed of interest to our users. SRS does not guarantee the accuracy, completeness or timeliness of the facts, analysis and opinions displayed, nor does it give investment advice, nor advocate the purchase or sale of any security or investment. In no event will Sagient Research Systems have liability of any kind (including, without limitation, for lost profits or trading losses) caused by, resulting from or relating to, the use of, or inability to use, any information obtained through BMT. BMT is a product of Sagient Research Systems

TRADEMARK

BioMedTracker is a registered service mark of SRS in the United States. Unless otherwise indicated, all service marks, trademarks, and logos, whether registered or not, as well as trade dress, located on this website ("Marks") are the sole and exclusive property of SRS. Other product and company names mentioned herein may be the trademarks of their respective owners. Users are not permitted to use these Marks without the prior written consent of SRS or such third party that may own the Mark. Fair use of SRS Marks in advertising and promotion of SRS products requires proper acknowledgment.

DISCLAIMER OF WARRANTIES AND LIABILITY

NEITHER SRS NOR ANY THIRD-PARTY SUPPLIERS OF DATA, SOFTWARE OR EQUIPMENT TO SRS MAKE ANY WARRANTY, EXPRESS OR IMPLIED, AS TO THE RESULTS TO BE OBTAINED BY ANY USER OR OTHERS FROM THE USE OF THE SERVICE PROVIDED HEREUNDER. SRS MAKES NO EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS OF THE SERVICE FOR A PARTICULAR PURPOSE OR USE.

The information contained in our database has been obtained from sources considered by SRS to be reliable. However, the accuracy and completeness thereof are not guaranteed and SRS and its third-party suppliers shall have no liability for errors or omissions with respect to the service or its delivery, regardless of the cause or source of such error or omission.

NEITHER SRS OR ANY OF ITS THIRD-PARTY SUPPLIERS SHALL HAVE ANY LIABILITY TO A USER OR TO OTHERS FOR ANY LOST PROFITS OR INDIRECT, SPECIAL, CONSEQUENTIAL, PUNITIVE OR EXEMPLARY DAMAGES, EVEN IF ADVISED IN ADVANCE OF THE POSSIBILITY OF SUCH DAMAGES.

SRS and its third party suppliers shall not be liable to the User for any delay or default in providing the BMT service resulting from any circumstances beyond its reasonable control. SRS may change or discontinue the BMT service, or its availability to you, at any time without notice. If any provision of this Agreement is invalid or unenforceable under applicable law, the remaining provisions will continue in full force and effect.